M
Myosin Therapeutics
Privately-held biopharmaceutical company developing novel medications targeting cellular motor proteins, specialized molecular machines that convert energy into mechanical work inside cells
About Myosin Therapeutics
Myosin Therapeutics, a biopharmaceutical company established in 2020, is the result of a collaboration between Dr. Courtney Miller, Dr. Pat Griffin, and Dr. Ted Kamenecka, all of whom have ties to Scripps Research. Dr. Miller, a neuroscientist, made a key discovery that underpins the company's focus: the identification of nonmuscle myosin II as a therapeutic target for conditions like methamphetamine use disorder.
The company is centered on the development of novel medications that target cellular motor proteins, specifically non-muscle myosin II (NMII). This protein is implicated in tumor proliferation and invasion, resistance to therapy, and oxidative stress. Myosin Therapeutics is leveraging this understanding to develop treatments for central nervous system-based disorders, with a particular emphasis on glioblastoma and substance use disorders.
One of the company's lead candidates, MT-125, is a selective inhibitor of NMII. In a significant milestone, Myosin Therapeutics received FDA clearance to initiate a first-in-human trial of MT-125 for the treatment of glioblastoma. The company has secured $3 million in seed funding to advance its research and development efforts.
Source: Dealroom company dataNews
Open roles
Myosin Therapeutics in the Jupiter ecosystem
The Myosin Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed8 investors entered at this stage
- MPMint12 Pharma
Florida Opportunity Fund
DeepWork Capital
Sontag foundation
Mayo Clinic Business Development
National Institutes of Health
National Cancer Institute (NCI)
Florida Department of Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Myosin Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Myosin Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

